GPR119
GPR119 receptors, also referred to as SNORF25, RUP3, GPCR2 and OSGPR116, are Gαs-protein-coupled receptors with a degree of homology to cannabinoid receptors. They are predominantly expressed in the pancreas and gastrointestinal tract in humans and rodents.
GPR119 Agonists |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 1484 | Oleylethanolamide |
| Endogenous GPR119 receptor agonist | |
GPR119 receptors, also referred to as SNORF25, RUP3, GPCR2 and OSGPR116, are Gαs-protein-coupled receptors with a degree of homology to cannabinoid receptors. They are predominantly expressed in the pancreas and gastrointestinal tract in humans and rodents. Ethanolamides are proposed to be the endogenous ligands for GPR119. Oleoylethanolamide (OEA) is the most potent endogenous GPR119 agonist identified to date, and the compound's effects on feeding are mediated through this receptor.
GPR119 receptors are proposed to play a role in glucose homeostasis through modulation of insulin secretion. Activation of GPR119 receptors potentiates glucose-stimulated insulin secretion in a manner analogous to that of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory poylpeptide (GIP). In addition, GPR119 agonists have been shown to directly stimulate GLP-1 and GIP secretion, which are both powerful antihyperglycemic agents.
GPR119 receptors are attracting attention from diabetes and obesity researchers, as receptor modulation may provide favorable effects on glucose homeostasis, food intake, weight gain and possibly β-islet cell preservation.